Safety and Efficacy of R0.6C Vaccine

Summary

This is a first-in-human phase I, open-label, single-site, dose escalation study to determine the safety, tolerability and Plasmodium falciparum transmission reducing activity of the R0.6C vaccine in two different adjuvant combinations.

Timeline

Start

2021-05-17

Primary completion

2022-06-29

Completion

2022-06-29

Publications

• Results Alkema M, Smit MJ, Marin-Mogollon C, Totte K, Teelen K, van Gemert GJ, van de Vegte-Bolmer M, Mordmuller BG, Reimer JM, Lovgren-Bengtsson KL, Sauerwein RW, Bousema T, Plieskatt J, Theisen M, Jore MM, McCall MBB. A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial. BMC Med. 2024 Apr 23;22(1):170. doi: 10.1186/s12916-024-03379-y.

Drugs

Indications